GABA B receptor upregulates fragile X mental retardation protein expression in neurons

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Wenhua ^a   Xu, Chanjuan ^a   Tu, Haijun ^a   Wang, Yunyun ^a   Sun, Qian ^a   Hu, Ping ^a   Hu, Yongjian ^a   Rondard, Philippe ^b   Liu, Jianfeng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN; FRAGILE X MENTAL RETARDATION PROTEIN; SOMATOMEDIN RECEPTOR;

ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NERVE CELL; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BACLOFEN; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION REGULATION; HUMANS; MICE; NEURONS; RECEPTORS, GABA-B; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION;

EID: 84930676992     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10468     Document Type: Article

References (44)

1. Bagni, C. & Greenough, W. T. From mRNP trafficking to spine dysmorphogenesis: The roots of fragile X syndrome. Nat Rev Neurosci 6, 376-87 (2005).
2. Pasciuto, E. & Bagni, C. SnapShot: FMRP mRNA targets and diseases. Cell 158, 1446-1446 e1 (2014).
3. Penagarikano, O., Mulle, J. G. & Warren, S. T. The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8, 109-29 (2007).
4. Braat, S. & Kooy, R. F. Fragile X syndrome neurobiology translates into rational therapy. Drug Discov Today 19, 510-9 (2014).
5. Costa, L. et al. Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol Psychiatry 72, 924-33 (2012).
6. Berry-Kravis, E. Mechanism-based treatments in neurodevelopmental disorders: Fragile X syndrome. Pediatr Neurol 50, 297-302 (2014).
7. Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 4, 152ra128 (2012).
8. Berry-Kravis, E. M. et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med 4, 152ra127 (2012).
9. Bettler, B., Kaupmann, K., Mosbacher, J. & Gassmann, M. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 84, 835-67 (2004).
10. Pin, J. P. et al. Activation mechanism of the heterodimeric GABA(B) receptor. Biochem Pharmacol 68, 1565-72 (2004).
11. Liu, J. et al. Molecular determinants involved in the allosteric control of agonist affinity in the GABAB receptor by the GABAB2 subunit. J Biol Chem 279, 15824-30 (2004).
12. Pin, J. P. et al. Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 272, 2947-55 (2005).
13. Chalifoux, J. R. & Carter, A. G. GABAB receptor modulation of synaptic function. Curr Opin Neurobiol 21, 339-44 (2011).
14. Tu, H. et al. Dominant role of GABAB2 and Gbetagamma for GABAB receptor-mediated-ERK1/2/CREB pathway in cerebellar neurons. Cell Signal 19, 1996-2002 (2007).
15. Tu, H. et al. GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation. J Neurosci 30, 749-59 (2010).
16. Lin, X. et al. An activity-based probe reveals dynamic protein-protein interactions mediating IGF-1R transactivation by the GABA(B) receptor. Biochem J 443, 627-34 (2012).
17. Pin, J. P. & Prezeau, L. Allosteric modulators of GABA(B) receptors: Mechanism of action and therapeutic perspective. Curr Neuropharmacol 5, 195-201 (2007).
18. Binet, V. et al. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J Biol Chem 279, 29085-91 (2004).
19. Urwyler, S. et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tertbutyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 60, 963-71 (2001).
20. Onali, P., Mascia, F. M. & Olianas, M. C. Positive regulation of GABA(B) receptors dually coupled to cyclic AMP by the allosteric agent CGP7930. Eur J Pharmacol 471, 77-84 (2003).
21. Wang, H., Wu, L. J., Zhang, F. & Zhuo, M. Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. J Neurosci 28, 4385-97 (2008).
22. Wang, H. et al. Roles of CREB in the regulation of FMRP by group I metabotropic glutamate receptors in cingulate cortex. Mol Brain 5, 27 (2012).
23. Carlezon Jr. W. A., Duman, R. S. & Nestler, E. J. The many faces of CREB. Trends Neurosci 28, 436-45 (2005).
24. Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. Sci Transl Med 4, 152ra128 (2012).
25. Johannessen, M., Delghandi, M. P. & Moens, U. What turns CREB on? Cell Signal 16, 1211-27 (2004).
26. Martiny-Baron, G. et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268, 9194-7 (1993).
27. Malherbe, P. et al. Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br J Pharmacol 154, 797-811 (2008).
28. Urwyler, S. et al. N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: Novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther 307, 322-30 (2003).
29. Urwyler, S., Gjoni, T., Koljatic, J. & Dupuis, D. S. Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: Effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 48, 343-53 (2005).
30. Braat, S. & Kooy, R. F. Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials. Neuropharmacology 88, 48-54 (2015).
31. Kandel, E. R. The molecular biology of memory: CAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. Mol Brain 5, 14 (2012).
32. Cha-Molstad, H., Keller, D. M., Yochum, G. S., Impey, S. & Goodman, R. H. Cell-type-specific binding of the transcription factor CREB to the cAMP-response element. Proc Natl Acad Sci USA 101, 13572-7 (2004).
33. Marie, H., Morishita, W., Yu, X., Calakos, N. & Malenka, R. C. Generation of silent synapses by acute in vivo expression of CaMKIV and CREB. Neuron 45, 741-52 (2005).
34. Martin, K. C. et al. Synapse-specific, long-term facilitation of aplysia sensory to motor synapses: A function for local protein synthesis in memory storage. Cell 91, 927-38 (1997).
35. Kida, S. et al. CREB required for the stability of new and reactivated fear memories. Nat Neurosci 5, 348-55 (2002).
36. Pasciuto, E. & Bagni, C. SnapShot: FMRP interacting proteins. Cell 159, 218-218 e1 (2014).
37. Jeon, S. J. et al. Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades. J Biomed Sci 18, 17 (2011).
38. Jeon, S. J. et al. Positive feedback regulation of Akt-FMRP pathway protects neurons from cell death. J Neurochem 123, 226-38 (2012).
39. Parsons, J. T. Focal adhesion kinase: The first ten years. J Cell Sci 116, 1409-16 (2003).
40. Garrett, A. M., Schreiner, D., Lobas, M. A. & Weiner, J. A. gamma-protocadherins control cortical dendrite arborization by regulating the activity of a FAK/PKC/MARCKS signaling pathway. Neuron 74, 269-76 (2012).
41. Jiang, X., Sinnett-Smith, J. & Rozengurt, E. Differential FAK phosphorylation at Ser-910, Ser-843 and Tyr-397 induced by angiotensin II, LPA and EGF in intestinal epithelial cells. Cell Signal 19, 1000-10 (2007).
42. Pontier, S. M. et al. Coordinated action of NSF and PKC regulates GABAB receptor signaling efficacy. EMBO J 25, 2698-709 (2006).
43. Pacey, L. K., Tharmalingam, S. & Hampson, D. R. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J Pharmacol Exp Ther 338, 897-905 (2011).
44. Filip, M. et al. GABAB receptors as a therapeutic strategy in substance use disorders: Focus on positive allosteric modulators. Neuropharmacology 88, 36-47 (2015).